Akums Drugs Granted Patent for Dual Release Gastro-Resistant Tablet
Filing Summary
Akums Drugs and Pharmaceuticals Ltd has been granted a patent for its “Dual Release Gastro-Resistant Composition” effective for 20 years starting November 19, 2022. This patent covers a new Dual Release Proton Pump Inhibitor (PPI) tablet designed to treat gastroesophageal reflux disease (GERD). The innovative tablet uses a tablet-in-tablet technology to ensure extended drug absorption and improved patient compliance. The formulation has received approval from the Drug Controller General of India (DCGI), reinforcing Akums’ focus on developing advanced therapies for chronic acid-related disorders.
Akums Drugs and Pharmaceuticals Ltd has announced the grant of a patent for its invention titled “Dual Release Gastro-Resistant Composition.” The patent is valid for a term of 20 years, commencing from November 19, 2022, as per the Patents Act, 1970. This development was communicated to the National Stock Exchange of India Ltd and BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The filing does not disclose specific financial terms or commercial arrangements related to the patent. There is no mention of revenue projections, cost implications, or financial commitments associated with the development or commercialization of the patented product.
The scope of the patent includes a Dual Release Proton Pump Inhibitor (PPI) tablet designed for the treatment of gastroesophageal reflux disease (GERD). This condition affects a significant portion of the global population, with an estimated 784 million individuals impacted as of 2019. The innovative tablet employs a tablet-in-tablet technology, releasing the drug in two phases: 50% in the duodenum and 50% in the ileum. This mechanism ensures extended drug absorption and prolonged duration of action. The formulation aims to provide consistent heartburn relief with a once-daily dosage.
The market context highlights GERD as a prevalent digestive disorder, affecting approximately 14% of the global population. In India, the prevalence is estimated at 15.6%. Conventional PPIs, such as Pantoprazole and Esomeprazole, are effective in reducing stomach acid but may not provide lasting relief, leading to nocturnal acid breakthrough. The dual release formulation addresses these limitations by offering improved stability and uniform drug release.
The timeline for the patent grant indicates that the application was filed on November 19, 2022, with the patent officially granted on October 31, 2025. The Drug Controller General of India (DCGI) has approved the formulation, allowing Akums to proceed with its development and potential market introduction.
Akums Drugs and Pharmaceuticals Ltd is focused on developing innovative pharmaceutical formulations. The company prioritizes creating patient-friendly therapies for chronic conditions, leveraging advanced technologies to enhance treatment efficacy and compliance. Akums continues to expand its portfolio with a commitment to addressing unmet medical needs in the healthcare sector.